Document Type

Journal Article

Department/Unit

School of Chinese Medicine

Language

English

Abstract

Cathepsin K (CatK) is one of the most potent proteases in lysosomal cysteine proteases family, of which main function is to mediate bone resorption. Currently, CatK is among the most attractive targets for anti-osteoporosis drug development. Although many pharmaceutical companies are working on the development of selective inhibitors for CatK, there is no FDA approved drug till now. Odanacatib (ODN) developed by Merck & Co. is the only CatK inhibitor candidate which demonstrated high therapeutic efficacy in patients with postmenopausal osteoporosis in Phase III clinical trials. Unfortunately, the development of ODN was finally terminated due to the cardio-cerebrovascular adverse effects. Therefore, it arouses concerns on the undesirable CatK inhibition in non-bone sites. It is known that CatK has far-reaching actions throughout various organs besides bone. Many studies have also demonstrated the involvement of CatK in various diseases beyond the musculoskeletal system. This review not only summarized the functional roles of CatK in bone and beyond bone, but also discussed the potential relevance of the CatK action beyond bone to the adverse effects of inhibiting CatK in non-bone sites.

Keywords

Cathepsin K, osteoclast, bone resorption, osteoporosis, osteoarthritis, Cathepsin K inhibitor, cardiovascular diseases, lung fibrosis

Publication Date

6-2020

Source Publication Title

Frontiers in Cell and Developmental Biology

Volume

8

Publisher

Frontiers Media

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

DOI

10.3389/fcell.2020.00433

Link to Publisher's Edition

https://doi.org/10.3389/fcell.2020.00433

ISSN (electronic)

2296634X

Share

COinS